Compare Dover Corp (DOV) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dover Corp vs 10X Genomics Inc — how do they compare? Dover Corp trades at $216.11 (market cap $28.84B), while 10X Genomics Inc trades at $45.96 (market cap $5.81B). The key difference: Dover Corp is far larger — about 5× 10X Genomics Inc's market cap, and Dover Corp pays a 0.97% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| DOV | TXG | |
|---|---|---|
Market Cap | $28.84B | $5.81B |
Sector | Industrials | Health |
52-Week High | $233.31 | $45.80 |
52-Week Low | $161.16 | $11.34 |
Enterprise Value | $30.49B | $5.36B |
Dividend Yield | 0.97% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dover Corporation (DOV) trades at $214.27, down 0.49% on the day, with a bearish technical signal and neutral oscillators. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS expected at $2.72. Financials show solid profitability with a 13.3% net income margin and 15.06% ROE, though cash flow turned negative in 2025. Recent news highlights product launches in fueling solutions and data center technologies, indicating ongoing innovation.
The outlook is mixed: strong analyst consensus (64% buy ratings) and a $250.67 price target suggest upside, but bearish technicals and negative net cash flow pose near-term risks. Investors should weigh robust fundamentals against market volatility and execution challenges in a competitive industrial sector.
TXG trades at $41.77, down 2.25% today, with a bullish technical setup supported by moving averages. The company shows improving fundamentals with revenue growth to $642.82M in 2025 and narrowing losses, while recent collaborations with Cleveland Clinic and the Proteintech acquisition expand its diagnostic capabilities. Analyst sentiment is mixed with 45% buy ratings but a consensus price target below current levels.
The outlook suggests cautious optimism as TXG demonstrates operational improvement with positive cash flow generation, though profitability remains elusive. Key risks include execution challenges in new ventures and competitive pressures, while upside potential hinges on continued margin expansion and successful integration of recent acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
